Late-Stage Trial Study of an Eli Lilly Coronavirus Drug to Begin in Nursing Homes
The Eli Lilly pharmaceutical company recently announced that it is starting a late-stage trial, involving 2,400 participants (residents and staff) in nursing homes, to study whether an experimental COVID-19 antibody treatment can prevent the virus’ spread in residents and staff.
